As of SAT, MAY 9, 3:14 PM · New Brief Daily
Last updated May 9, 2026 — I read this morning's peptide research and picked the items that mattered. Fresh brief tomorrow.
*Attia's peptide AMA draws the clearest clinical-evidence line yet from a mainstream longevity physician.*
Research VialsWhat CAS registry numbers are, why they matter for peptide identification, and how to use them to verify compound identity across suppliers.
PubMed · BMJ open diabetes research & careViolante-Ortiz R et al., BMJ open diabetes research & care · 2026 Mar 30. PMID 41912265.
Lifespan.ioA new study finds dasatinib + quercetin, the widely self-administered senolytic stack, produces demyelination-like damage in specific brain regions of mice — a finding that should give pause to anyone cycling D+Q without clinical oversight. The authors stop short of extrapolating to humans but call for more CNS-focused safety work.
Aging CellAging Cell's latest review consolidates the case that preserving lean mass during caloric deficit is not cosmetic — it is mechanistically linked to metabolic resilience, immune competence, and all-cause mortality risk. The paper lands as GLP-1 agonist-driven weight loss raises industry-wide questions about muscle loss as collateral damage.
Lifespan.ioA new study finds creatine supplementation layered onto power training amplifies certain training adaptations in older adults beyond what exercise alone produces. The findings add weight to creatine's expanding evidence base as a peptide-adjacent performance and aging compound.
Lifespan.ioT cells may retain a pro-inflammatory phenotype long after normal weight is restored following obesity — a finding with direct implications for GLP-1-driven weight loss patients who assume metabolic normalization equals immune normalization. Duration of this effect in humans remains an open question.
Dr Michael MoellerDr. Moeller ranks the top 7 weight-loss peptides — tirzepatide, semaglutide, retatrutide, tesamorelin and others — by clinical evidence, real-world outcomes, and risk-versus-reward, with notes on which compounds actually move the needle for fat loss versus body composition.
Dr Jones DCBook your free discovery call *HERE:* https://drjonesdc.com/yt1d Body recomposition isn’t just about dropping the number on the scale. The real goal is losing fat while preserving or building lean muscle, and that requires the right biolo
Cortex LabsEach week we put clips together of highlights of the last week's livestream! In this one we dive deep into a number of TRT topics we all know and love. Let's get into it!! 💥🚀 Hire me to resolve Libido/EQ/Sensation issues on TRT, HRT, or
Dr Debra DurstWomen have been told for decades that gynecology is about reproduction, disease management, and prevention. But what about pleasure? What about sex? What about the part of women's health that nobody in a traditional practice has time — or t
Dr Trevor BachmeyerWhy Retatrutide Feels Weaker After Tirzepatide (And How to Fix It) I explain why many people feel retatrutide “doesn’t work” after switching from tirzepatide, explaining the issue is biology, not the molecule. I contrast tirzepatide’s GLP-
Dr LivingoodFasted walking already burns about 70% more fat than walking after a meal — but most people are leaving a lot on the table by stopping there. In this video, I walk you through six specific hacks you can stack on top of your fasted walk to m
Research VialsMOTS-c, SS-31, and the emerging class of mitochondria-targeted peptides. How they work, what they target, and why mitochondrial medicine is growing.
Lifespan.ioRockefeller University's Junyue Cao details how ultra-high-throughput single-cell sequencing is generating the first comprehensive atlas of aging across human tissues — a foundational dataset for targeting senescent cell accumulation with precision interventions. The interview covers where the technology is heading and what it means for peptide and senolytic research.
Lifespan.ioResearchers in Aging Cell have mapped the bidirectional relationship between intestinal epithelial aging and microbiome dysbiosis — showing that age-related mucosal changes actively favor pathobiont colonization. The findings reinforce gut-targeted peptide strategies like GLP-2 and KPV as mechanistically relevant beyond simple inflammation reduction.
BluePrint (Bryan Johnson)Bryan Johnson's team publishes a breakdown of the evidence base behind his skin aging protocol, acknowledging that most commercial skin creams lack clinical backing. The piece highlights where the evidence is strongest and what compounds made the cut — relevant to readers tracking GHK-Cu and peptide-based aesthetic applications.
Peter AttiaAttia's latest AMA covers NAD supplementation alongside metabolic health, strength training efficiency, and dementia risk — a signal that NAD's role in the longevity stack is getting more rigorous clinical scrutiny from mainstream physicians. His take on where the evidence is solid vs. speculative is characteristically direct.
Peter AttiaThe first trial pairing rapamycin with structured exercise produces underwhelming results, but Attia argues a single negative trial doesn't invalidate the geroprotection hypothesis. His analysis of why the trial design may have obscured real signal is essential reading for anyone following mTOR-pathway longevity research.
eLifeeLife researchers have used in vivo fiber photometry to record real-time kisspeptin neuron population activity across the estrous cycle in mice, confirming that prolonged oscillatory firing in RP3V neurons underlies the GnRH surge that triggers ovulation. The mechanistic granularity here is directly relevant to kisspeptin's emerging therapeutic role in reproductive endocrinology.
Fight Aging!Altos Labs, the $3 billion Yamanaka-factor reprogramming venture, is actively raising its public profile after years of opacity. Fight Aging! parses what this shift signals about the company's timeline and the state of partial reprogramming as a longevity therapy.
Fight Aging!New mouse data evaluates a class of IGF-1 receptor inhibitors for their ability to modulate the growth-hormone/IGF axis toward modest lifespan extension — a well-trodden but still active frontier in longevity pharmacology with direct relevance to GH secretagogue research.
Fight Aging!Fight Aging! synthesizes evidence that inflammaging — the chronic low-grade immune activation of aging — is a primary upstream driver of neurodegenerative pathology, not merely a downstream consequence. Thymic peptides and immune-modulatory compounds like Thymosin Alpha 1 sit directly in this mechanistic conversation.
Fight Aging!A thorough review of AGEs as drivers of chronic inflammation, tissue crosslinking, and RAGE-mediated signaling — directly intersecting with research on BPC-157 and GHK-Cu's roles in tissue repair and extracellular matrix maintenance.
Fight Aging!New evidence reinforces that aged muscle satellite cells retain regenerative capacity when removed from the aged niche — pointing to systemic and local signaling, not irreversible cell-intrinsic damage, as the primary block to muscle regeneration in older adults.
Nature Agingp21+TREM2+ senescent macrophages are identified as key instigators of hepatic inflammaging and MASLD progression — adding cellular resolution to the case for targeted senolytic strategies in metabolic disease.
Research VialsResearch overview of Melanotan peptides — melanocortin receptor agonists studied for pigmentation pathways, photoprotection, and related endocrine signaling.
